RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05430399, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: women only

    Registered eligibility fields

  2. Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;

    Inclusion criterion 3

    The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;

    Inclusion criterion 4

  3. For HR+ breast cancer patients shall meet one of the two criteria below: a) radiographically confirmed recurrence or progression within 2 years of adjuvant endocrine therapy; b) received at least one line of endocrine therapy in the recurrence or metastasis stage;

    Inclusion criterion 9

  4. Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization;

    Inclusion criterion 7

    Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia were allowed ;

    Inclusion criterion 10

    Women of childbearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;

    Inclusion criterion 15

    Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;

    Exclusion criterion 3

    Experienced grade ≥ 3 nervous system-related adverse events after treatment with anti-microtubule drugs;

    Exclusion criterion 5

  5. Eastern Cooperative Oncology Group (ECOG) score [0-1] points;

    Inclusion criterion 5

  6. Patients must have metastatic disease that is evaluable on imaging: including at least one measurable lesion (assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)); or only non-measurable disease as defined by RECIST 1.1 , especially in patients with bone metastases only, while the disease could be documented/assessed by bone scan, PET or MRI;

    Inclusion criterion 6

  7. Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;

    Exclusion criterion 2

  8. Pregnant or lactating women;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05430399, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed the informed consent form;
  • Women aged ≥ 18 years;
  • Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;
  • The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;
  • Eastern Cooperative Oncology Group (ECOG) score [0-1] points;
  • Patients must have metastatic disease that is evaluable on imaging: including at least one measurable lesion (assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)); or only non-measurable disease as defined by RECIST 1.1 , especially in patients with bone metastases only, while the disease could be documented/assessed by bone scan, PET or MRI;
  • Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization;
  • No previous chemotherapy for advanced breast cancer ;
  • For HR+ breast cancer patients shall meet one of the two criteria below: a) radiographically confirmed recurrence or progression within 2 years of adjuvant endocrine therapy; b) received at least one line of endocrine therapy in the recurrence or metastasis stage;
  • Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia were allowed ;
  • Patients with asymptomatic CNS metastases may be enrolled, if:
  • Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or
  • Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ;
  • Adequate hematological, hepatic and renal function;
  • Women of childbearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;
  • Life expectancy of at least 12 weeks;
  • Patients must be able to participate and comply with treatment and follow up.

Exclusion Criteria:

  • HER-2 positive (IHC 3+, or FISH positive);
  • Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
  • Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;
  • Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study;
  • Experienced grade ≥ 3 nervous system-related adverse events after treatment with anti-microtubule drugs;
  • Symptomatic central nervous system metastases;
  • Pregnant or lactating women;
  • Known or suspected hypersensitivity to any of the study drugs or excipients;
  • Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ;
  • Any other condition that the investigator considers inappropriate to participate in this trial .
  • Use of corticosteroids is prohibited.

Quoted from ClinicalTrials.gov, NCT05430399, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05430399, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05430399